Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
Ameloblastoma
Immunotherapy
MAPK pathway
PD-L1
Targeted therapy
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
02
10
2023
accepted:
05
10
2023
medline:
23
10
2023
pubmed:
11
10
2023
entrez:
10
10
2023
Statut:
ppublish
Résumé
Although complete excision is the standard of care for ameloblastoma, a subset of recurrent and/or metastasizing ameloblastomas are difficult to treat surgically. Over the past decade, several recurrent mutations in the mitogen-activated protein kinase pathway genes have been identified in ameloblastoma, based on which the efficacy of targeted therapy has been investigated. However, most of the literature has focused on BRAF V600E mutations, the most common oncogenic mutations in ameloblastoma. Hence, this study aims to review the current knowledge of targetable genetic alterations in ameloblastoma from a broader perspective. In addition, the therapeutic potential of immunotherapy for ameloblastoma will be briefly discussed in the context of tumoral PD-L1 expression and the tumor immune microenvironment.
Identifiants
pubmed: 37816291
pii: S1368-8375(23)00281-6
doi: 10.1016/j.oraloncology.2023.106585
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Review
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
106585Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.